In nearly one third of cancer patients receiving erythropoiesis-stimulating agents (ESAs) in the United States, the use of the blood-cell-boosting agents was either too short or too long.

Results from a trial of patients with early-stage breast cancer have reignited discussions over the use of erythropoiesis-stimulating agents (ESAs) for chemotherapy-induced anemia, but experts ...

Cancer progression ESAs can make cancers of the breast, cervix, lung, head, neck, and lymph nodes progress more rapidly, according to several trials of people undergoing chemotherapy for those ...

BACKGROUND: Cancer patients often develop the potentially debilitating condition of anaemia. Numerous controlled studies indicate that erythropoiesis-stimulating agents (ESAs) can raise ...

Learn more about cancer-related anemia, including its causes, symptoms, and treatments. Skip to main content . ... You'll only get ESAs if you're having a certain kind of chemotherapy.

Patients treated with high-dose ESAs had a 77% increased likelihood of cancer compared with those not exposed to ESAs, Dr Lafrance’s team reported online in Nephrology Dialysis Transplantation.

SMART-ESAS: Smartphone Monitoring and Assessment in Real Time of Edmonton Symptom Assessment System Scores for ... 25-300 km). The most common primary cancer was breast cancer (29.7%), followed in ...

ESAS-r Cancer assesses symptoms identified by the National Comprehensive Cancer Network 44 and others 29 as important to regularly screen for and has the advantage of being a validated measure.

A US regulatory advisory panel has recommended further restrictions on the use of Amgen and Johnson & Johnson’s anaemia drugs in cancer patients but the news could have been worse for the drugmakers.